September 2013 : Concerns: Another Vaccine Trial Shuts Down - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Older and Wiser

Mandating Mail-Order Pharmacies

From the Editor

Touch of Gray

Feedback

Letters-September 2013

The POZ Q+A

Committed to the Fight

POZ Planet

Lost Worlds

We the LGBTHIV...

Testing the Limits

Say What-Dan Savage

Check Them Out

Try the Power of Bareback and Body

Burden of Proof

Citizen Scientists

Voices

Light and Darkness

Care and Treatment

GMHC Treatment Issues September 2013

Caring Docs Retain Patients

Breaking the Blood-Brain Barrier

HIV Capsid Structure Defined

Found: Those Lost to Follow-up

Combo of Two HIV Drugs Can Control Hep B

Research Notes

Prevention: Repurposing Vaginal Gel for Rectal Use

Treatment: Pot--the Next HIV Drug?

Cure: Misleading Reports Say Cure Is Near

Concerns: Another Vaccine Trial Shuts Down

POZ Survey Says

Ourselves, Growing Older

POZ Heroes

Musical Missionary

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

September 2013

Concerns: Another Vaccine Trial Shuts Down

by Benjamin Ryan

In the latest setback in the search for an HIV vaccine, a major trial has closed down after the experimental vaccine failed both to prevent HIV transmission and to reduce viral load in those who contracted the virus. An independent review board found that more people receiving the vaccine became infected with the virus than those receiving the placebo—although this difference was not statistically significant and may have been the result of chance. Called HVTN 505, the Phase IIb study was conducted by the HIV Vaccine Trials Network, which is sponsored by the National Institute of Allergy and Infectious Diseases. Beginning in 2009, it enrolled 2,504 men who have sex with men and transgendered people from across the United States. The trial follows on the heels of the RV 144 vaccine trial, which reduced infection rates among heterosexuals in Thailand by 30 percent, but which was itself brought to a close in 2009 because its protection rate was still not high enough.

Search: HIV vaccine, HVTN 505, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    koffeeboss
    Tucson
    Arizona


    Sexynyrican
    Brooklyn
    New York


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.